Titre : Dynamine-II

Dynamine-II : Questions médicales fréquentes

Termes MeSH sélectionnés :

Retinal Detachment
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dynamine-II : Questions médicales les plus fréquentes", "headline": "Dynamine-II : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dynamine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dynamine-II" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dynamines", "url": "https://questionsmedicales.fr/mesh/D034281", "about": { "@type": "MedicalCondition", "name": "Dynamines", "code": { "@type": "MedicalCode", "code": "D034281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.990.400" } } }, "about": { "@type": "MedicalCondition", "name": "Dynamine-II", "alternateName": "Dynamin II", "code": { "@type": "MedicalCode", "code": "D034285", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ya-Wen Liu", "url": "https://questionsmedicales.fr/author/Ya-Wen%20Liu", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Center of Precision Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: yawenliu@ntu.edu.tw." } }, { "@type": "Person", "name": "Marc Bitoun", "url": "https://questionsmedicales.fr/author/Marc%20Bitoun", "affiliation": { "@type": "Organization", "name": "Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France." } }, { "@type": "Person", "name": "Adam McCluskey", "url": "https://questionsmedicales.fr/author/Adam%20McCluskey", "affiliation": { "@type": "Organization", "name": "Chemistry, School of Environmental & Life Sciences, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia." } }, { "@type": "Person", "name": "Jessica Laiman", "url": "https://questionsmedicales.fr/author/Jessica%20Laiman", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan." } }, { "@type": "Person", "name": "Hong Cao", "url": "https://questionsmedicales.fr/author/Hong%20Cao", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Factors associated with postoperative visual function after rhegmatogenous retinal detachment with foveal detachment.", "datePublished": "2024-09-20", "url": "https://questionsmedicales.fr/article/39302973", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0308863" } }, { "@type": "ScholarlyArticle", "name": "Increased intraocular pressure secondary to retinal detachment.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36371054", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.oftale.2022.08.011" } }, { "@type": "ScholarlyArticle", "name": "Outer Retinal Corrugations in Rhegmatogenous Retinal Detachment: The Retinal Pigment Epithelium-Photoreceptor Dysregulation Theory.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36067852", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.08.019" } }, { "@type": "ScholarlyArticle", "name": "Symptom-Based Risk Factors for Retinal Tears and Detachments in Suspected Posterior Vitreous Detachment.", "datePublished": "2022-10-13", "url": "https://questionsmedicales.fr/article/36228586", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000527295" } }, { "@type": "ScholarlyArticle", "name": "Characteristics and surgical outcomes of giant retinal tear associated rhegmatogenous retinal detachment.", "datePublished": "2024-08-27", "url": "https://questionsmedicales.fr/article/39198536", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-70898-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Protéines du transport vésiculaire", "item": "https://questionsmedicales.fr/mesh/D033921" }, { "@type": "ListItem", "position": 6, "name": "Dynamines", "item": "https://questionsmedicales.fr/mesh/D034281" }, { "@type": "ListItem", "position": 7, "name": "Dynamine-II", "item": "https://questionsmedicales.fr/mesh/D034285" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dynamine-II - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dynamine-II", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dynamine-II", "description": "Comment diagnostiquer une anomalie de Dynamine-II ?\nQuels tests sont utilisés pour évaluer la Dynamine-II ?\nY a-t-il des marqueurs spécifiques pour la Dynamine-II ?\nQuels symptômes peuvent indiquer un problème avec Dynamine-II ?\nLes tests génétiques sont-ils fiables pour Dynamine-II ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dynamine-II", "description": "Quels sont les symptômes d'une déficience en Dynamine-II ?\nLa Dynamine-II affecte-t-elle le système nerveux ?\nY a-t-il des signes cliniques spécifiques ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on observer des symptômes respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dynamine-II", "description": "Peut-on prévenir les anomalies de Dynamine-II ?\nLe dépistage prénatal est-il possible ?\nLes conseils génétiques sont-ils recommandés ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes habitudes de vie influencent-elles la Dynamine-II ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dynamine-II", "description": "Quels traitements sont disponibles pour les anomalies de Dynamine-II ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider ?\nLa rééducation est-elle bénéfique ?\nY a-t-il des essais cliniques en cours ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dynamine-II", "description": "Quelles complications peuvent survenir avec Dynamine-II ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dynamine-II", "description": "Quels sont les facteurs de risque pour les anomalies de Dynamine-II ?\nL'âge joue-t-il un rôle dans les anomalies de Dynamine-II ?\nY a-t-il des prédispositions génétiques ?\nLes facteurs environnementaux influencent-ils ?\nLes habitudes de vie affectent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Retinal+Detachment&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de Dynamine-II ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la Dynamine-II ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'immunoblotting et la microscopie électronique pour visualiser les anomalies." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour la Dynamine-II ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de marqueurs spécifiques largement reconnus pour la Dynamine-II." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec Dynamine-II ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques ou musculaires peuvent indiquer une anomalie de Dynamine-II." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils fiables pour Dynamine-II ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent fournir des informations précises sur les mutations de Dynamine-II." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en Dynamine-II ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, troubles de la coordination et problèmes neurologiques." } }, { "@type": "Question", "name": "La Dynamine-II affecte-t-elle le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de Dynamine-II peuvent entraîner des troubles neurologiques significatifs." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques spécifiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'atrophie musculaire et des réflexes anormaux peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience." } }, { "@type": "Question", "name": "Peut-on observer des symptômes respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes respiratoires peuvent survenir en raison de la faiblesse musculaire." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies de Dynamine-II ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthodes de prévention connues pour les anomalies de Dynamine-II." } }, { "@type": "Question", "name": "Le dépistage prénatal est-il possible ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage prénatal peut être envisagé si des antécédents familiaux sont présents." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques associés." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis pour Dynamine-II." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles la Dynamine-II ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuves solides que les habitudes de vie influencent directement Dynamine-II." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies de Dynamine-II ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont principalement symptomatiques et peuvent inclure la physiothérapie." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais n'est pas encore une option standard pour Dynamine-II." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent aider à gérer les symptômes, mais aucun n'est spécifique à Dynamine-II." } }, { "@type": "Question", "name": "La rééducation est-elle bénéfique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation physique peut améliorer la force et la coordination chez les patients." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques en cours ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent de nouvelles approches thérapeutiques pour Dynamine-II." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Dynamine-II ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles moteurs, des problèmes respiratoires et des infections." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de maladies neuromusculaires associées." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies de Dynamine-II ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de maladies génétiques sont un facteur de risque majeur." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans les anomalies de Dynamine-II ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer l'apparition des symptômes, mais n'est pas un facteur de risque direct." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations spécifiques dans le gène de la Dynamine-II peuvent prédisposer aux anomalies." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, l'impact des facteurs environnementaux sur Dynamine-II n'est pas bien compris." } }, { "@type": "Question", "name": "Les habitudes de vie affectent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuves solides que les habitudes de vie influencent le risque de Dynamine-II." } } ] } ] }

Sources (6520 au total)

Factors associated with postoperative visual function after rhegmatogenous retinal detachment with foveal detachment.

To investigate pre-, intra-, and postoperative factors influencing postoperative visual acuity, degree of metamorphopsia, and retinal sensitivity after vitrectomy in patients with rhegmatogenous retin... We reviewed retrospectively 33 consecutive eyes of 32 patients, who underwent vitrectomy for rhegmatogenous retinal detachment with foveal detachment between August 2018 and October 2020 and obtained ... Preoperative total retinal detachment was the only factor significantly associated with worse best-corrected visual acuity at 1-year postoperatively (β = 0.589, P<0.001). Intraoperative internal limit... Our study findings suggest that best-corrected visual acuity, metamorphopsia, and retinal sensitivity at 1 year after vitrectomy for rhegmatogenous retinal detachment with foveal detachment are influe...

Outer Retinal Corrugations in Rhegmatogenous Retinal Detachment: The Retinal Pigment Epithelium-Photoreceptor Dysregulation Theory.

Outer retinal folds occur when outer retinal corrugations (ORCs) persist after retinal reattachment with worse functional outcomes. We investigate the pathophysiology of ORCs in vivo.... Prospective cohort study.... Patients with rhegmatogenous retinal detachment (RRD) presenting to St. Michael's Hospital, Toronto, Ontario, Canada, between August 2020 and February 2022 were assessed with swept-source optical cohe... Sixty-six patients were included. More than half (60.6%, 40/66) were fovea-off and 48.4% (32/66) had ORCs at presentation. All eyes (32/32) with ORCs had retinal pigment epithelium (RPE)-photoreceptor... ORCs develop with (1) acute exposure of subretinal space to liquified vitreous, (2) for >2 days, that (3) overwhelms RPE capacity, leading to progressive and extensive RRD. Mathematical models suggest...

Symptom-Based Risk Factors for Retinal Tears and Detachments in Suspected Posterior Vitreous Detachment.

The aim of this study was to determine symptom-level risk factors for retinal tear/retinal detachment (RT/RD) in our patients presenting with symptoms of posterior vitreous detachment (PVD).... We conducted a prospective cohort study of patients presenting to outpatient ophthalmology clinics at a single academic institution with complaint(s) of flashes, floaters, and/or subjective field loss... We recruited 237 patients (age 20-93 years) from March 2018 to March 2019. The most common diagnosis was PVD (141, 59.5%), followed by vitreous syneresis (38, 16.0%) and RT/RD (34, 14.3%). Of those wi... While well-known demographic and exam-based risk factors for RT/RD exist in patients with PVD symptoms, the relative importance of symptom characteristics is less clear. We found that the presence of ...

Outer Retinal Hyperreflective Dots: A Potential Imaging Biomarker in Rhegmatogenous Retinal Detachment.

To investigate hyperreflective dots (HRDs) on baseline OCT in rhegmatogenous retinal detachment (RRD).... Retrospective cohort study.... Consecutive primary fovea-off RRDs presenting between January 2012 and September 2022.... Visual acuity (VA) was obtained at baseline, 3, 6, and 12 months. Baseline foveal OCT scans were graded for the presence of HRDs in the outer retina, morphologic stage of RRD in the parafovea, and fov... The primary outcome was the proportion of patients in each morphologic stage with HRDs present on OCT and their association with postoperative VA. Secondary outcomes included association with the heig... A total of 351 patients were included. The presence of HRDs by morphologic stage of RRD was 0% in stage 1, 4.5% (2/42) in stage 2, 13% (7/54) in stage 3a, 16% (20/126) in stage 3b, 48% (40/83) in stag... Hyperreflective dots have been hypothesized to consist of intraretinal inflammatory cells. We found that HRDs were significantly associated with the morphologic stage, extent, duration, and height of ... The author(s) have no proprietary or commercial interest in any materials discussed in this article....

Expansile gas concentration in primary pseudophakic retinal detachment repair, effect on intraocular pressure and outcomes; the Manchester Pseudophakic Retinal Detachment Study.

To investigate the effect of isovolumetric and expansile gas tamponade concentrations on single surgery anatomical success (SSAS) and day 1 intraocular pressure (IOPD1) following pars plana vitrectomy... We conducted a single-centre retrospective continuous and comparative study on eyes that had undergone small-gauge PPV using isovolumetric versus expansile gas for PRD repair between 2011 and 2020 at ... From 456 eyes, PSM analysis matched 240 eyes with 120 in each group. The median (interquartile range) follow-up was 96 (59 to 218) days. The SSAS was 229/240 (95.8%) overall; 115/120 (95.8%) and 114/1... Expansile gas concentration does not impact SSAS but is associated with significantly raised IOPD1 with no reduction in hypotony rates following PPV for primary PRD....

Retinal detachment in a child with Frank-ter Haar syndrome.

To present a rare case of ocular involvement in a child with Frank-ter Haar syndrome (FTHS) presenting retinal detachment.... Detailed ophthalmological evaluation including examination under general anesthesia, ocular ultrasound, and visual evoked potential testing was completed. Photographic documentation of the physical fi... A 3-year-old female patient with FTHS was referred to evaluate for possible ophthalmic involvement. The patient presented with the classical dysmorphic abnormalities of the syndrome. Ophthalmologic ev... FTHS is associated with multiple ocular involvement such as megalocornea, congenital glaucoma, or colobomas. This case report is the first to describe a high, against-the-rule astigmatism and retinal ...